Dr. JessicaJLinMD at #RomeLung25 updates treatment for #ALK NSCLC. Many TKIs approved, PFS greatest for lorlatinib but NVL-655 (neladalkib) emerging as an active agent in later lines and will be compared to alectinib in 1L in phase 3 trial.

Three years ago today, I had absolutely no idea what had just hit me. Stage 4 ALK Positive Lung Cancer at just 35 years of age? What on earth was that? Even now, I’m not sure I have better answers. I’ve learned to navigate this so-called “new normal,” but let’s be honest—it’s

🚨 Happening now at #ASCO25! The Lung Cancer Rapid Oral Abstract session features key updates on ALK+ #NSCLC 🫁 📗 From a review in the Targeted Therapies in NSCLC supplement: ALK therapies are improving survival and changing treatment: acsjournals.onlinelibrary.wiley.com/doi/epdf/10.10… OncoAlert

🚨 ALNEO (Ph II) at #ASCO25: Neoadj alectinib (8w) → surgery → adj (96w) in stage III ALK+ NSCLC (n=33) Encouraging response — but how neo is neo enough❓ 🎯 MPR 42% | pCR 12% ▪️ORR 67% | nodal downstaging in 48% ▪️85% underwent surgery | R0: 86% ✋🏼mEFS/OS not reached (mFUP:

ALK+ #lungcancer community: your experience is powerful. 💪   Join the ALK Life Study—the world’s largest ALK+ cancer registry—and help fuel research that leads to real breakthroughs.   This #ALKPositiveAwarenessMonth, be #PoweredByPatients. 🔗 alkpositive.org/survey-registry   #LCSM

Dr. Alice Shaw has studied ALK+ #lungcancer since its discovery in 2007. With approx 40K people diagnosed yearly worldwide & many patients out of options after targeted therapy, the need for breakthroughs is urgent. This #APAM, join us in being #PoweredByPatients. 💪 #LCSM

Managing lorlatinib together: An overview and practical guide for patients by ALK-positive NSCLC patients and medical experts doi.org/10.1016/j.lung… ALKPositiveIndia Together4Cancer Lung Connect India #lcsm

Meet Colin Barton, awarded our inaugural Spirit of Courage Award for exemplifying our mission, value & community. He’s the only ALK member to have been to every Summit since 2018, he founded our charity & medical community, & inspires so many. Congrats Colin 💙 #LCSM

#ALKSummit25 KOL panel: What’s the role of local consolidation therapy in ALK+ #lungcancer? Dr D. Ross Camidge shares his views: “It’s not necessarily for everyone. How far do we push it? Should we consolidate w chemotherapy? Lots of questions & variables.” #LCSM #StrongerTogether

At #ALKSummit25 Dana-Farber’s Nancy Campbell says: We hear that “exercise is medicine” & now the CHALLENGE trial confirms it’s true. The good news is not much more required than sneakers & 3-4 brisk 45-60 min walks per week to improve survival. #StrongerTogether #LCSM

Dr Dr Sofia Merajver, MS, MD, PhD ☮️ opens day 2 of the #ALKSummit25 discussing all of U-M Rogel Cancer Center’s increíble ALK+ cancer research. Proud to have had a blood draw this year to advance this work. Our 2nd year running! #StrongerTogether

✨ What a weekend!✨ Our 2025 ALK+ Summit wrapped up today — but the connections, knowledge & hope keep going strong. Thank you for showing up & reminding us we’re #StrongerTogether. Stay tuned for more moments from this unforgettable weekend! 💙 #ALKSummit25 #LCSM

Tomorrow is World Lung Cancer Day 🫁 We’re honoring it with a shirt designed by our Healing Arts Coordinator, Dana Querido, representing all lung cancers. Proceeds fuel research, hope & awareness through ALK Positive Inc. 🛒 Order now : bonfire.com/lung-cancer-aw…

Our award-winning See Through the Symptoms campaign is back! Launched today for World Lung Cancer Day, the campaign returns with a brand-new website and updated materials - ready to support early diagnosis in primary care. Photographed by Rankin and winner of Public Health

Today on #WorldLungCancerDay I want you to know that lung cancer is NOT just a disease of smokers. Increasingly it is happening in young, fit, non-smokers like me. We need urgent answers from research & attention in the policy space. Else we can forget about our demographic

Today is World Lung Cancer Day We stand with those facing it. We remember those we’ve lost. We speak up for those who don’t have the words yet. Lung cancer is the leading cause of cancer death worldwide Research matters. And every single life impacted by this disease matters

Many in the ALK+ community now start lorlatinib first line or later. Managing side effects can be challenging — patients need clear, practical info. Our VP Nancee Pronsati & Dr. Ken Culver co-authored a patient guide w leading KOLs. Learn more👇 alkpositive.org/blog/managing-… #LCSM

ALK Positive Summer Farmen Yvonne Diaz Pfizer Inc. ALKPositiveIndia alkpositivebelgium ALK Positive Australia Inc. UKALK+ Young Lung Cancer Initiative Ben Solomon So many patients can be afraid to share their side effects with their care teams over fears of being taken off their drugs. We often have questions about effectiveness around dose reductions. Great to have this patient-led guide. 🩵